An Overview of the Current Understanding and Management of the Non-Hodgkin’s Lymphomas

  • Ellen R. Gaynor
  • John E. Ultmann
Part of the NATO ASI Series book series (NSSA, volume 120)


The hematologic malignancies have always provided the model tumor system tor the oncologist. These tumors traditionally have been among the most responsive to chemotherapy and hence chemotherapeutic developments stemmed largely from knowledge gained from the management of these diseases. What has been lacking is an understanding of the malignant process itself and so while we have been able to control and often cure these diseases, a void has existed in our understanding of basic pathophysiology. The past several years have brought tremendous developments in the fields of cytogenetics, immunology, molecular biology, and virology. Whereas previously we have been able to speak of these diseases in merely descriptive terms, we are now quickly gaining an understanding of the events leading to the phenomenon of malignant transformation. It is apparent that once the process is understood, it will be merely a matter of time before we are better able to control the process. While the gap between basic pathophysiology information and therapeutic application is a reality, it probably will not be an insurmountable hurdle.


Chronic Lymphocytic Leukemia Complete Remission Rate Hairy Cell Leukemia Adoptive Immunotherapy Immunoglobulin Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. Fox, Remarks on the presentation of microscopical preparations made from some original tissue described by Thomas Hodgkin, 1832. Annals of Medical History, 8: 370 (1926).Google Scholar
  2. 2.
    H. Rappaport, Tumors of the hemopoietic system, in: “Atlas of Tumor Pathology”, Armed Forces Institute of Pathology, Washington, D.C. (1966).Google Scholar
  3. 3.
    R. J. Lukes, and R. D. Collins, New approaches to the classification of the lymphomata, Br. J. Cancer, 31 (Supp1.2): 1 (1975).Google Scholar
  4. 4.
    R. Gerard-Marchant, I. Hamlin, K. Lennert, F. Rilke, A. C. Stans- field, and J. A. Van Unik, Classification of non-Hodgkin’s lymphomas, Lancet 2:406–409 (1974) [Letter to the editor].Google Scholar
  5. 5.
    Non-Hodgkin’s Lymphoma Pathologic Classification Project, National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage, Cancer 49: 2112 (1982).CrossRefGoogle Scholar
  6. 6.
    A. Arnold, J. Cossman, A. Bakhshi, E. Jaffe, T. A. Waldmann, and S. J. Korsmeyer, Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms, N. Engl. J. Med., 309: 1593 (1983).PubMedCrossRefGoogle Scholar
  7. 7.
    T. A. Waldmann, S. J. Korsmeyer, A. Bakhshi, A. Arnold, and J. R. Kirsch, Molecular genetic analysis of human lymphoid neoplasms, Ann. Intern. Med., 102: 497 (1985).PubMedGoogle Scholar
  8. 8.
    I. T. Magrath, Lymphocyte differentiation: an essential basis tor the comprehension of lymphoid neoplasia, JNCI, 67: 501 (1981).Google Scholar
  9. 9.
    G. Manalov, and Y. Manalova, Marker band in one chromosome 14 from Burkitt lymphoma, Nature, 237: 33 (1972).CrossRefGoogle Scholar
  10. 10.
    Y. Manalova, G. Manalov, J. Kieler, A. Lenan, and G. Klein, Genesis of the 14q+ marker in Burkitt’s lymphoma, Hereditas, 90: 5 (1979).CrossRefGoogle Scholar
  11. 11.
    H. Van den Berghe, C. Parloir, S. Gosseye, V. Englebienne, G. Carnu, and G. Sokal, Variant translocation in Burkitt lymphoma, Cancer Genet. Cytogenet., 1: 9 (1979).CrossRefGoogle Scholar
  12. 12.
    R. Berger, A. Bernheim, H. J. Web, G. Flandren, M. T. Daniel, J. C. Brovet, and N. Colbert, A new translation in Burkitt’s tumor cells, Hum. Genet., 53: 111 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    J. R. Kirsch, C. C. Morton, K. Nakahara, and P. Leder, Human immunoglobulin heavy chain genes map to a region of translocations in malignant B lymphocytes, Science, 216: 303 (1982).CrossRefGoogle Scholar
  14. 14.
    S. Malcolm, P. Barton, C. Murphy, M. A. Ferguson-Smith, D. L. Bentley and T. H. Rabbits, Localization at human immunoglobulin kappa light chain variable region genes to the short arm of chromosome 2 by in situ hybridizations, Proc. Nat. Acad. Sci. USA, 79: 4957 (1982).PubMedCrossRefGoogle Scholar
  15. 15.
    J. Erickson, J. Martinus, and C. M. Croce, Assignment of the genes for human lambda immunoglobulin chains to chromosome 22, Nature, 294: 173 (1981).CrossRefGoogle Scholar
  16. 16.
    R. Dalla-Favera, M. Bregni, J. Erikson, D. Pattereson, R. C. Gallo, and C. M. Croce, Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells, Proc. Nat. Acad. Sci. USA, 19: 7824 (1982).CrossRefGoogle Scholar
  17. 17.
    G. Klein, Specific chromosomal translocations and the genesis of beta-cell derived tumor in mice and men, Cell, 32: 311 (1983).PubMedCrossRefGoogle Scholar
  18. 18.
    J. J. Yunis, M. M. Oken, M. E. Kaplan, K. M. Ensrud, R. R. Howe, and A. Theologidas, Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin’s lymphomas, N. Engl. J. Med., 307: 1231 (1982).PubMedCrossRefGoogle Scholar
  19. 19.
    C. D. Bloomfield, D. C. Arthur, E. G. Frizzera, B. A. Peterson, and K. J. Gajl-Peczalska, No random chromosome abnormalities in lymphoma, Cancer Res., 43: 2975 (1983).PubMedGoogle Scholar
  20. 20.
    H. Temin, and S. Mizutani, RNA-dependent DNA pclymerase in virions of Rous sarcoma virus, Nature, 226: 1211 (1970).PubMedCrossRefGoogle Scholar
  21. 21.
    D. A. Morgan, F. W. Ruscetti, and R. C. Gallo, Selective in vitro growing of T-lymphocytes from normal human bone marrow, Science, 193: 1007 (1983).CrossRefGoogle Scholar
  22. 22.
    F. Wong-Staal, and R. C. Gallo, The family of human T-lymphotrophic leukemia virus: HTLV-I as the cause of adult T cell leukemia and HTLV-III as the cause of acquired immunodeficiency syndrome, Blood, 65: 253 (1985).PubMedGoogle Scholar
  23. 23.
    B. R. Smith, D. S. Weinberg, N. J. Robert, M. Towle, E. Luther, G. S. Pinkus, and K. A. Ault, Circulating monoclonal B lymphocytes in non-Hodgkin’s lymphoma, N. Engl. J. Med., 311: 1476 (1984).PubMedCrossRefGoogle Scholar
  24. 24.
    C. S. Portlock, S. A. Rosenberg, E. Glatstein, and H. S. Kaplan, Treatment of advanced non-Hodgkin’s lymphoma with favorable histologies: preliminary results of a prospective trial, Blood, 47: 747 (1976).PubMedGoogle Scholar
  25. 25.
    C. S. Portlock, and S. A. Rosenberg, No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann. Intern. Med., 90: 10 (1979).PubMedGoogle Scholar
  26. 26.
    T. Anderson, R. A. Bender, R. I. Fisher, V. T. DeVita, B. A. Chabner, C. W. Bernard, L. Norton, and R. C. Young, Combination chemotherapy in non-Hodgkin’s lymphoma: results of long-term follow-up. Cancer Treat. Rep., 6: 1057 (1977).Google Scholar
  27. 27.
    J. H. Glick, J. M. Barnes, E. Z. Ezdinli, C. W. Berard, E. L. Orlow, J. M. Bennett, Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy, Blood, 58: 920 (1981).PubMedGoogle Scholar
  28. 28.
    M. Coleman, Chemotherapy tor large cell lymphoma: Optimism and caution, Ann. Intern. Med., 103:140 (1985) [editorial].Google Scholar
  29. 29.
    J. O. Armitage, F. R. Dick, M. P. Corder, S. C. Garneau, C. E. Platz, and D. J. Slymen, Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), Cancer, 50: 1695 (1982).PubMedCrossRefGoogle Scholar
  30. 30.
    V. T. DeVita, G. P. Canellos, B. Chabner, P. Schein, S. P. Hubbard, and R. C. Young, Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy, Lancet, 1: 248 (1975).PubMedCrossRefGoogle Scholar
  31. 31.
    P. S. Schein, V. T. DeVita, S. P. Hubbard, B. A. Chabner, G. P. Canellos, and C. W. Berard, Bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma, Ann. Intern. Med., 85: 417 (1976).PubMedGoogle Scholar
  32. 32.
    D. L. Sweet, H. M. Golomb, J. E. Ultmann, J. B. Miller, R. S. Stein, E. P. Lester, U. Mintz, J. D. Bitran, R. A. Streuli, K. Daly, and N. O. Roth, Cyclophosphamide, vincristine, methotrexate with leucovorin rescue and cytarabine (COMLA) combination sequential chemotherapy tor advanced diffuse histiocytic lymphoma, Ann. Intern. Med., 92: 785 (1980).PubMedGoogle Scholar
  33. 33.
    A. T. Skarin, G. P. Canellos, D. S. Rosenthal, D. C. Case, J. M. Maclntyre, G. S. Pinkus, W. C. Moloney, and E. Frei, Improved prognosis of diffuse histiocytic lymphoma by use of high dose methotrexate alternating with standard agents, J. Clin. Oncol., 1: 91 (1983).PubMedGoogle Scholar
  34. 34.
    J. H. Goldi, A. J. Goldman, and G. A. Gudauskas, Rationale for the use of alternating non-cross-resistant chemotherapy, Cancer Treat. Rep., 66: 39 (1982).Google Scholar
  35. 35.
    A. Santoro, G. Bonnadonna, and V. Bonfante, Alternating drug combinations in the treatment of advanced Hodgkin’s disease, N. Engl. J. Med., 306: 770 (1982).PubMedCrossRefGoogle Scholar
  36. 36.
    R. I. Fisher, V. T. DeVita, S. M. Hubbard, D. L. Long, R. Wesley, B. Chabner, and R. C. Young, Diffuse aggressive lymphomas, increased survival after alternating flexible sequences of ProMace and MOPP chemotherapy, Ann. Intern. Med., 98: 304 (1983).PubMedGoogle Scholar
  37. 37.
    P. Klimo, and J. M. Connors, MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma, Ann. Intern. Med., 102: 596 (1985).Google Scholar
  38. 38.
    G. Kohler, and C. Milstein, Continous cultures of fused cells secreting antibody of predefined specifiticy, Nature, 256: 495 (1975).PubMedCrossRefGoogle Scholar
  39. 39.
    L. M. Nadler, P. Stashenko, R. Hardy, W. D. Kaplan, L. N. Button, D. W. Kufe, K. H. Antman, and S. F. Schlossman, Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen, Cancer Res., 40: 3147 (1980).PubMedGoogle Scholar
  40. 40.
    R. A. Miller, and R. Levy, Response of cutaneous T cell lymphoma therapy with hybridoma monoclonal antibody, Lancet, 2: 226 (1981).PubMedCrossRefGoogle Scholar
  41. 41.
    R. A. Miller, D. G. Maloney, R. Warnke, and R. Levy, Treatment of B cell lymphoma with monoclonal anti-idiotype antibody, N. Engl. J. Med., 306: 517 (1982).PubMedCrossRefGoogle Scholar
  42. 42.
    M. Raffeld, L. Neckers, D. L. Longo, and J. Cossman, Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma: escape from detection by anti-idiotype, N. Engl. J. Med., 312: 1653 (1985).PubMedCrossRefGoogle Scholar
  43. 43.
    J. Ritz, and S. F. Schlossman, Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma, Blood, 59: 1 (1982).PubMedGoogle Scholar
  44. 44.
    S. Sherwin, K. Foon, P. Bunn, D. Longo, and R. Oldham, Recombinant leukocyte A interferon in the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and mycosis fungoides, Proc. Amer. Soc. Hematol., 62: 764 (1983).Google Scholar
  45. 45.
    H. Ozer, R. Leavett, V. Ratanatharathorn, J. E. Ultmann, C. Portlock, D. L. Kisner, R. Ferraresi, S. A. Rudnick, and E. M. Bonnem, Experience in the use of DNA a2-interferon in the treatment of malignant lymphomas, Proc. Amer. Soc. Heoratol., 62: 761 (1983).Google Scholar
  46. 46.
    R. Ferraresi, S. A. Rudnick, E. M. Bonnem, J. Ochs, C. Karenes, V. Ratanatharathorn, and S. S. Costanzi, Enhanced response to chemotherapy after treatment with DNA a2 human interferon, Proc. Amer. Soc. Hematol., 62: 752 (1983).Google Scholar
  47. 47.
    H. Golomb, A. Fefer, M. Ratain, J. Thompson, H. Ozer, C. Portlock, R. Spiegel, and J. Brady, A Recombinant a2 interferon for the treatment of hairy cell leukemia, Proc. Amer. Clin. Oncology, 4: 874 (1985).Google Scholar
  48. 48.
    W. F. H. Jarrett, E. M. Crawford, W. B. Martin, and F. David, A virus like particle associated with leukemia (lymphosarcoma), Nature, 202: 567 (1964).PubMedCrossRefGoogle Scholar
  49. 49.
    S. A. Rosenberg, Adoptive immunotherapy of cancer: accomplishments and prospects, Cancer Treat. Rep., 68: 233 (1984).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Ellen R. Gaynor
    • 1
  • John E. Ultmann
    • 1
  1. 1.Department of MedicineUniversity of Chicago and the University of Chicago Cancer Research CenterChicagoUSA

Personalised recommendations